AGIO Relative Valuation
AGIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AGIO is overvalued; if below, it's undervalued.
Historical Valuation
Agios Pharmaceuticals Inc (AGIO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.85. The fair price of Agios Pharmaceuticals Inc (AGIO) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：27.42
Fair
-3.67
PE
1Y
3Y
5Y
Trailing
Forward
-0.76
EV/EBITDA
Agios Pharmaceuticals Inc. (AGIO) has a current EV/EBITDA of -0.76. The 5-year average EV/EBITDA is -2.48. The thresholds are as follows: Strongly Undervalued below -6.92, Undervalued between -6.92 and -4.70, Fairly Valued between -0.26 and -4.70, Overvalued between -0.26 and 1.96, and Strongly Overvalued above 1.96. The current Forward EV/EBITDA of -0.76 falls within the Historic Trend Line -Fairly Valued range.
-0.74
EV/EBIT
Agios Pharmaceuticals Inc. (AGIO) has a current EV/EBIT of -0.74. The 5-year average EV/EBIT is -2.44. The thresholds are as follows: Strongly Undervalued below -6.83, Undervalued between -6.83 and -4.63, Fairly Valued between -0.24 and -4.63, Overvalued between -0.24 and 1.96, and Strongly Overvalued above 1.96. The current Forward EV/EBIT of -0.74 falls within the Historic Trend Line -Fairly Valued range.
22.21
PS
Agios Pharmaceuticals Inc. (AGIO) has a current PS of 22.21. The 5-year average PS is 375.63. The thresholds are as follows: Strongly Undervalued below -2209.47, Undervalued between -2209.47 and -916.92, Fairly Valued between 1668.18 and -916.92, Overvalued between 1668.18 and 2960.73, and Strongly Overvalued above 2960.73. The current Forward PS of 22.21 falls within the Historic Trend Line -Fairly Valued range.
-5.46
P/OCF
Agios Pharmaceuticals Inc. (AGIO) has a current P/OCF of -5.46. The 5-year average P/OCF is -5.42. The thresholds are as follows: Strongly Undervalued below -14.07, Undervalued between -14.07 and -9.75, Fairly Valued between -1.09 and -9.75, Overvalued between -1.09 and 3.24, and Strongly Overvalued above 3.24. The current Forward P/OCF of -5.46 falls within the Historic Trend Line -Fairly Valued range.
-4.89
P/FCF
Agios Pharmaceuticals Inc. (AGIO) has a current P/FCF of -4.89. The 5-year average P/FCF is -5.60. The thresholds are as follows: Strongly Undervalued below -18.73, Undervalued between -18.73 and -12.17, Fairly Valued between 0.96 and -12.17, Overvalued between 0.96 and 7.52, and Strongly Overvalued above 7.52. The current Forward P/FCF of -4.89 falls within the Historic Trend Line -Fairly Valued range.
Agios Pharmaceuticals Inc (AGIO) has a current Price-to-Book (P/B) ratio of 1.24. Compared to its 3-year average P/B ratio of 1.84 , the current P/B ratio is approximately -32.31% higher. Relative to its 5-year average P/B ratio of 2.09, the current P/B ratio is about -40.33% higher. Agios Pharmaceuticals Inc (AGIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -18.95%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -18.75% , the current FCF yield is about -100.00% lower.
1.24
P/B
Median3y
1.84
Median5y
2.09
-25.83
FCF Yield
Median3y
-18.95
Median5y
-18.75
Competitors Valuation Multiple
The average P/S ratio for AGIO's competitors is 0.00, providing a benchmark for relative valuation. Agios Pharmaceuticals Inc Corp (AGIO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 43.69%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AGIO decreased by 16.56% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.67 to -3.94.
The secondary factor is the Revenue Growth, contributed 43.69%to the performance.
Overall, the performance of AGIO in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Agios Pharmaceuticals Inc (AGIO) currently overvalued or undervalued?
What is Agios Pharmaceuticals Inc (AGIO) fair value?
How does AGIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Agios Pharmaceuticals Inc (AGIO) as of Dec 05 2025?
What is the current FCF Yield for Agios Pharmaceuticals Inc (AGIO) as of Dec 05 2025?
What is the current Forward P/E ratio for Agios Pharmaceuticals Inc (AGIO) as of Dec 05 2025?